How EVO301’s Unique IL-18 Binding Mechanism and Phase 2a Results Could Target Unmet Needs in AD

Mark Jackson, MD, Senior Vice President of Clinical Development at Evommune and clinical professor at the University of Louisville School of Medicine, sat down with Dermatology Times to give a pipeline update on EVO301, an investigational treatment for atopic dermatitis (AD).

Jackson highlighted the persistent unmet need in the treatment of moderate to severe AD, emphasizing real-world challenges in managing patients who fail currently available therapies. Despite the utility of established options such as IL-4/IL-13 inhibitors and JAK inhibitors, Jackson noted that a subset of patients continues to experience inadequate disease control or tolerability issues, underscoring the need for additional therapeutic mechanisms and improved efficacy.

EVO30 is an investigational agent designed with a novel mechanism of action targeting IL-18 through a unique binding protein that mimics the body’s endogenous binding interactions. Unlike traditional monoclonal antibodies, EVO301 incorporates a serum albumin–linked fragment to extend half-life, enhance tissue penetration, and improve localization to inflamed skin. This design may also reduce immunogenicity and the development of neutralizing antibodies, potentially translating into improved durability and consistency of response.

Clinical findings from a phase 2a study demonstrated encouraging efficacy signals, particularly given the severity of the study population, which included patients with extensive disease involvement and high baseline Eczema Area and Severity Index (EASI) scores averaging near 30. Notably, patients received only 2 doses of EVO301, yet improvements were observed as early as week 2, with statistically significant efficacy achieved by week 4 and sustained through weeks 8 and 12, even after treatment cessation.

Equally important, the safety profile was favorable, with no reported cases of conjunctivitis, infusion reactions, or systemic safety concerns. Jackson suggests that, if maintained in larger studies, this profile could position EVO301 as a best-in-class option from a tolerability standpoint.

Looking ahead, planned phase 2b studies will evaluate a subcutaneous formulation with optimized dosing regimens to further enhance efficacy while maintaining safety. Overall, Jackson emphasized that EVO301 represents a promising addition to the evolving AD treatment landscape, with the potential to expand first-line options and address the ongoing need for higher levels of skin clearance in this disease.

“We feel like EVO301 brings a potential new first-line option,” he concluded. “It doesn't have to be the first line option, but we want to bring it forward as a first line option based on its safety, tolerability, and efficacy.”